Clinical trial

Vorinostat, Carboplatin, and Paclitaxel in Treating Patients With Advanced or…

NCT00481078 · National Cancer Institute (NCI), NIH · Completed

Key facts

NCT number NCT00481078
Title Vorinostat, Carboplatin, and Paclitaxel in Treating Patients With Advanced or Metastatic Non-Small Cell Lung Cancer
Official title Randomized Phase II Study of Vorinostat or Placebo in Combination With Carboplatin and Paclitaxel for Patients With Advanced or Metastatic Non-Small Cell Lung Cancer
Lead sponsor National Cancer Institute (NCI), NIH
Status Completed
Phase Phase 2
Study type Interventional
Conditions Recurrent Non-small Cell Lung Cancer, Stage IIIB Non-small Cell Lung Cancer, Stage IV Non-small Cell Lung Cancer
Intervention type Drug, Other
Interventions vorinostat, paclitaxel, carboplatin, placebo, laboratory biomarker analysis
Enrollment 94
Start date May 1, 2007
Primary completion Jul 1, 2009
Completion Jul 1, 2009
First posted Jun 1, 2007
Last update posted Oct 30, 2014
Countries United States

At a glance

  • 1–9 Study sites
  • Yes Results posted
  • None Linked FDA submissions

Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.

About ClinicalTrials.gov studies

ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.

Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date:

Browse all ClinicalTrials.gov studies